Enhancing FibroScan® liver disease assessment with biological markers.
Based on clinical literature.
A Single Biomarker cannot answer all questions. You can combine your FibroScan® results with other patient specific parameters to get clinically based stratification of your patients.
Scores Calculators are available to calculate Fast, Agile 3+, & Agile 4.
Suspected MASLD patients (Formerly NAFLD)
MASH + NAS≥4 + F≥2
Screening for clinical trial and identifying at-risk MASH patients
FibroScan® results (LSM by VCTE™ & CAP™) + laboratory parameter (AST)
Fast is a formula published and validated in multiple studies. Fast: princeps paper - Newsome et al., Lancet
Suspected MASLD patients
F≥3
Identifying MASLD patients with advanced fibrosis and predicting risk of complications
LSM by VCTE™ + Clinical parameters (AST, ALT, Platelets, Presence of Diabetes, Age and Gender)
Agile 3+: Princeps paper - Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan based Agile scores, Journal of Hepatology, 2022Gastroenterology Hepatology 2020;5(4):362-73
Suspected MAFLD patients
F4
Identifying MAFLD patients with cirrhosis that need to be screen for HCC
LSM by VCTE™ + Clinical parameters (AST, ALT, Platelets, Presence of Diabetes and Gender)
Agile 4: Princeps paper - Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan based Agile scores, Journal of Hepatology, 2022Gastroenterology Hepatology 2020;5(4):362-73
The non-invasive solution for comprehensive management of liver health
Cloud-based solution to assist clinicians in providing comprehensive liver care.
Your everyday FibroScan® companion – free application
Fast, Agile 3+ and Agile 4 Calculators are registered class 1 devices (FDA). myFibroScan is a Non-Device Medical Device Data Systems (MDDS). Fast Calculator, Agile 3+ Calculator, and Agile 4 Calculator are intended to compute their respective scores.
The Fast, Agile 3+ and Agile 4 scores were developed based on pools of cohorts and are published in peer-reviewed literature. They are taken from clinical literature and utilize proprietary FibroScan® measurements in their execution. While these scores are about specific medical and health issues, Echosens does not represent them as substitutes for, or replacements of personalized medical advice, or to be used as the sole basis for making individualized medical or health-related decisions.
FibroScan®
